ABAnkush Bhatia

Ankush Bhatia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ankush Bhatia has a total of 122 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Symptomatic plateau waves in a patient with leptomeningeal metastases captured with quantitative electroencephalography and intracranial pressure monitoring

    by Krithi Gopinath, Isabelle Renteria, Samantha Probelsky, Maryam Mahmood, Mustafa Basree, Jerdan Ruff, Brett Morris, Bradley Nix, Ankush Bhatia

  • Open Access

    Remote computer-adaptive patient-reported outcomes in patients with IDH-mutant grade 2 and 3 gliomas: a pilot study

    by Ankush Bhatia, William Adams, Antonio Dono, Yoshua Esquenazi, Krithi Gopinath, Kristen Clemons, Veena Nair, Pallavi Tiwari, Vivek Prabhakaran, Jane S. Paulsen

  • Open Access

    Radiographic Enhancing Progression Without Molecular or Histologic Progression in IDH‐Mutant Grade 2 Astrocytoma Treated With an IDH Inhibitor: A Case Report

    by Carolina Pusec, Karam Han, Krithi Gopinath, Michelle Mackay, Alan Lozier, Tejus A. Bale, Ankush Bhatia

    Central nervous system (CNS) World Health Organization (WHO) Grade 2 isocitrate dehydrogenase (IDH)‐mutant astrocytomas are classified as low‐grade gliomas with typically slow growth for many years followed by eventual malignant transformation and death. Here, we present a case of a patient with an IDH‐mutant Grade 2 astrocytoma who developed early radiographic tumor progression per Response Assessment in Neuro‐Oncology (RANO) 2.0 as evidenced by new enhancement on MRI T1 postcontrast 4 months after initiation of an IDH inhibitor. Subsequent re‐resection, one month later (or five months postinitiation of ivosidenib treatment), of the enhancing signal retained the Grade 2 designation without any histological or molecular progression per CNS WHO 2021 criteria. Specifically, the Ki‐67 proliferative index remained stable at approximately 2%, and copy number alterations were largely unchanged, including no CDKN2A/B homozygous deletion and relatively low chromosome copy number complexity. On histological examination, there was no elevation in mitotic activity and no features of necrosis or microvascular proliferation to suggest a more aggressive phenotype. The tumor demonstrated increased gemistocytic morphology and rare foci of foamy macrophages, as compared to prior. Following the second resection, the patient received sequential radiation therapy and adjuvant temozolomide chemotherapy treatment and has remained clinically stable on observation with surveillance MRIs for over 18 months. This case highlights the importance of re‐resection in IDH‐mutant gliomas, identifies the potential limitations of the response assessment criteria to differentiate treatment effect from true tumor progression, and emphasizes the need for ongoing investigation into novel genetic alterations, molecular signatures, and histologic markers to more accurately predict radiographic tumor behavior and guide more personalized, targeted treatment strategies for patients with IDH‐mutant gliomas.

  • Tumor Volume Growth as Surrogate Endpoint in IDH-mt Glioma—Response

    by Ankush Bhatia, Raquel Moreno, Anne S. Reiner, Subhiksha Nandakumar, Henry S. Walch, Rachna Malani, Katherine S. Panageas, Ingo K. Mellinghoff, Tejus A. Bale, Robert J. Young

    Historically the choice of a modeling framework for the growth of brain tumor volume has been disputed, lacking a clear consensus (1–4). In our recent manuscript in Clinical Cancer Research (1), we explored both linear and exponential volume growth models and observed an excellent fit for each, with a marginal preference for the exponential model (1). Dr. Mandonnet's suggestion to consider linear modeling of tumor diameter over time is well-taken from his response to our manuscript as well as from his prior studies on glioma growth (3–5).In addressing Dr. Mandonnet's inquiry, we characterized the growth of tumor diameter over time by performing linear mixed modeling. We incorporated an interaction term for 1p19q status to assess the differences in diameter growth between patients with intact versus codeleted tumors. Analyses were performed in SAS v9.4 (Cary, NC).Across our entire cohort, we observed an estimated diameter growth rate of 2.2 mm per year [95% confidence interval (CI), 1.9–2.5 mm]. Consistent with our original findings, there was no discernible difference in diameter growth rates by 1p19q status. Patients with intact tumors had an estimated diameter growth rate of 2.4 mm per year (95% CI, 1.9–3.0 mm), whereas patients with codeleted tumors had an estimated diameter growth rate of 2.1 mm per year (95% CI, 1.8–2.4 mm; P value = 0.25).Dr. Mandonnet and we have recognized the advantages and shortcomings of modeling diameter growth (1, 4). Although the approach is straightforward, it tends to overestimate volume, especially in cases with tumor contour irregularity. The cubic and exponential models share the characteristics that they are convex and upward sloping functions. Therefore, in the presence of noise, distinguishing the two may be challenging or impossible. Regardless of the modeling framework, our findings did not demonstrate a statistically significant difference based on 1p19q status in postoperative glioma growth rates; rather only a trend towards faster growth in 1p19q non-codeleted gliomas. We thank Dr. Mandonnet for his interest in our work and his modeling suggestion, and we wholeheartedly agree on the importance of integrating tumor kinetics into the management of patients with IDH-mutated glioma. We believe our work advances this mission by characterizing postoperative growth of these tumors, and, importantly, incorporating molecular genetics.See the original Letter to the Editor, p. 638A. Bhatia reports serving on the advisory board for Servier outside the submitted work. A.S. Reiner reports grants from NIH during the conduct of the study. I.K. Mellinghoff reports serving as a consultant for 501c3 Global Coalition for Adaptive Research; honoraria from the Doris Duke Charitable Foundation; serving on advisory board for Black Diamond Therapeutics, Roche Therapeutics, Prelude Therapeutics Incorporated, Voyager Therapeutics; research support from Erasca Therapeutics, Servier Pharmaceuticals LLC, Kazia Therapeutics, Vigeo Therapeutics, and Samus Therapeutics, Inc. R.J. Young reports personal fees from ICON plc, NordicNeuroImaging; and personal fees from Olea Sphere outside the submitted work. No disclosures were reported by the other authors. Historically the choice of a modeling framework for the growth of brain tumor volume has been disputed, lacking a clear consensus (1–4). In our recent manuscript in Clinical Cancer Research (1), we explored both linear and exponential volume growth models and observed an excellent fit for each, with a marginal preference for the exponential model (1). Dr. Mandonnet's suggestion to consider linear modeling of tumor diameter over time is well-taken from his response to our manuscript as well as from his prior studies on glioma growth (3–5).In addressing Dr. Mandonnet's inquiry, we characterized the growth of tumor diameter over time by performing linear mixed modeling. We incorporated an interaction term for 1p19q status to assess the differences in diameter growth between patients with intact versus codeleted tumors. Analyses were performed in SAS v9.4 (Cary, NC).Across our entire cohort, we observed an estimated diameter growth rate of 2.2 mm per year [95% confidence interval (CI), 1.9–2.5 mm]. Consistent with our original findings, there was no discernible difference in diameter growth rates by 1p19q status. Patients with intact tumors had an estimated diameter growth rate of 2.4 mm per year (95% CI, 1.9–3.0 mm), whereas patients with codeleted tumors had an estimated diameter growth rate of 2.1 mm per year (95% CI, 1.8–2.4 mm; P value = 0.25).Dr. Mandonnet and we have recognized the advantages and shortcomings of modeling diameter growth (1, 4). Although the approach is straightforward, it tends to overestimate volume, especially in cases with tumor contour irregularity. The cubic and exponential models share the characteristics that they are convex and upward sloping functions. Therefore, in the presence of noise, distinguishing the two may be challenging or impossible. Regardless of the modeling framework, our findings did not demonstrate a statistically significant difference based on 1p19q status in postoperative glioma growth rates; rather only a trend towards faster growth in 1p19q non-codeleted gliomas. We thank Dr. Mandonnet for his interest in our work and his modeling suggestion, and we wholeheartedly agree on the importance of integrating tumor kinetics into the management of patients with IDH-mutated glioma. We believe our work advances this mission by characterizing postoperative growth of these tumors, and, importantly, incorporating molecular genetics.See the original Letter to the Editor, p. 638A. Bhatia reports serving on the advisory board for Servier outside the submitted work. A.S. Reiner reports grants from NIH during the conduct of the study. I.K. Mellinghoff reports serving as a consultant for 501c3 Global Coalition for Adaptive Research;...


  • Open Access

    Supplementary Table S1 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma

    by Ankush Bhatia, Raquel Moreno, Anne S. Reiner, Subhiksha Nandakumar, Henry S. Walch, Teena M. Thomas, Philip J. Nicklin, Ye Choi, Anna Skakodub, Rachna Malani, et al.

    Supplementary Table S1. Alterations in Molecular-Grade High Group IDH-mutant Gliomas.

  • Open Access

    Supplementary Table S1 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma

    by Ankush Bhatia, Raquel Moreno, Anne S. Reiner, Subhiksha Nandakumar, Henry S. Walch, Teena M. Thomas, Philip J. Nicklin, Ye Choi, Anna Skakodub, Rachna Malani, et al.

    Supplementary Table S1. Alterations in Molecular-Grade High Group IDH-mutant Gliomas.

  • Open Access

    Supplementary Table S3 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma

    by Ankush Bhatia, Raquel Moreno, Anne S. Reiner, Subhiksha Nandakumar, Henry S. Walch, Teena M. Thomas, Philip J. Nicklin, Ye Choi, Anna Skakodub, Rachna Malani, et al.

    Supplementary Table S3. Baseline Radiological Characteristics Stratified by Molecular Grade.

  • Open Access

    Supplementary Table S2 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma

    by Ankush Bhatia, Raquel Moreno, Anne S. Reiner, Subhiksha Nandakumar, Henry S. Walch, Teena M. Thomas, Philip J. Nicklin, Ye Choi, Anna Skakodub, Rachna Malani, et al.

    Supplementary Table S2. Baseline Radiological Characteristics Overall and Stratified by 1p19q Status.

  • Open Access

    Data from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma

    by Ankush Bhatia, Raquel Moreno, Anne S. Reiner, Subhiksha Nandakumar, Henry S. Walch, Teena M. Thomas, Philip J. Nicklin, Ye Choi, Anna Skakodub, Rachna Malani, et al.

    Purpose:Isocitrate dehydrogenase–mutant (IDH-mt) gliomas are incurable primary brain tumors characterized by a slow-growing phase over several years followed by a rapid-growing malignant phase. We hypothesized that tumor volume growth rate (TVGR) on MRI may act as an earlier measure of clinical benefit during the active surveillance period.Experimental Design:We integrated three-dimensional volumetric measurements with clinical, radiologic, and molecular data in a retrospective cohort of IDH-mt gliomas that were observed after surgical resection in order to understand tumor growth kinetics and the impact of molecular genetics.Results:Using log-linear mixed modeling, the entire cohort (n = 128) had a continuous %TVGR per 6 months of 10.46% [95% confidence interval (CI), 9.11%–11.83%] and a doubling time of 3.5 years (95% CI, 3.10–3.98). High molecular grade IDH-mt gliomas, defined by the presence of homozygous deletion of CDKN2A/B, had %TVGR per 6 months of 19.17% (95% CI, 15.57%–22.89%) which was significantly different from low molecular grade IDH-mt gliomas with a growth rate per 6 months of 9.54% (95% CI, 7.32%–11.80%; P < 0.0001). Using joint modeling to comodel the longitudinal course of TVGR and overall survival, we found each one natural logarithm tumor volume increase resulted in more than a 3-fold increase in risk of death (HR = 3.83; 95% CI, 2.32–6.30; P < 0.0001).Conclusions:TVGR may be used as an earlier measure of clinical benefit and correlates well with the WHO 2021 molecular classification of gliomas and survival. Incorporation of TVGR as a surrogate endpoint into future prospective studies of IDH-mt gliomas may accelerate drug development.

  • Open Access

    Supplementary Table S3 from Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma

    by Ankush Bhatia, Raquel Moreno, Anne S. Reiner, Subhiksha Nandakumar, Henry S. Walch, Teena M. Thomas, Philip J. Nicklin, Ye Choi, Anna Skakodub, Rachna Malani, et al.

    Supplementary Table S3. Baseline Radiological Characteristics Stratified by Molecular Grade.